Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVV009 in transfusion-dependent primary cold agglutinin disease
NL-OMON50716Phase 3Active, not recruiting
- Sponsor
- Bioverativ Inc.
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of sutimlimab in cold agglutinin disease (CAD) (2 arms), sponsored by Bioverativ Inc. Primary endpoints: Responder rate and Long-term safety and tolerability. Started Sep 2018; status: active, not recruiting.
02
Drugs
sutimlimab
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NL-OMON50716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50716.